- Coordinator
- Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca, Spain
- Runs
- 1 June 2026 to 31 May 2032
- Status
- Running
- EU funding
- €8.5m
- Total cost
- —
- Partners
- 16 organisations in 6 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101289276
What the project is doing
In the project's own words, from its summary on CORDIS.
Childhood cancer is the leading cause of disease-related death in children, with high-risk neuroblastoma and other aggressive paediatric solid tumours representing a critical unmet need. Despite multimodal therapy, over half of children with relapsed or refractory disease do not achieve long-term survival, and those who do often suffer severe, lifelong toxicities. There is an urgent need for safer and more effective therapies.
Ibrilatazar (ABTL0812) is a first-in-class, orally administered anticancer agent that induces tumour cell death through endoplasmic reticulum stress and cytotoxic autophagy. Unlike conventional genotoxic chemotherapies, it spares DNA, offering a potentially safer profile highly relevant in children. In adult patients with advanced solid tumours, ibrilatazar has shown an excellent safety record and early efficacy in Phase I/II trials, with long-term stabilisation in heavily pre-treated patients, thereby supporting its evaluation in the paediatric population.
Preclinical studies in neuroblastoma models, including MYCN-amplified and chemoresistant cell lines, demonstrate that ibrilatazar reduces tumour growth, downregulates MYCN expression, and enhances standard chemotherapies and differentiating agents. Building on this evidence, PHOENIX will conduct a first-in-child, multicentre Phase I/II clinical trial of ibrilatazar in relapsed/refractory neuroblastoma and other aggressive solid tumours.
The trial will test combinations with irinotecan-temozolomide and selected immunotherapies (anti-GD2, anti-VEGF), aligned with our preclinical findings. In parallel, a comprehensive translational programme will integrate pharmacokinetic, pharmacodynamic, genomic, and immunological biomarker studies, aiming to enable patient stratification, early treatment monitoring, and improved trial inclusiveness by addressing social determinants of health.
Thus, PHOENIX seeks to deliver a safer, more effective therapeutic alternative for children with high-risk cancers. This action is part of the Cancer Mission cluster of projects on “Diagnosis and Treatment - innovative clinical trials for paediatric cancer.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca | Barcelona | Spain | Coordinator |
| Fakultni Nemocnice Brno | Brno | Czechia | Participant |
| Masarykova univerzita | Brno | Czechia | Third party |
| Region Hovedstaden | Hillerod | Denmark | Participant |
| Ability Pharmaceuticals SA | Barcelona | Spain | Participant |
| Fundacion Para La Investigacion Biomedica Del Hospital Universiatrio La Paz | Madrid | Spain | Third party |
| Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus | Madrid | Spain | Participant |
| Fundacion Para La Investigacion De Malaga En Biomedicina Y Salud | Malaga | Spain | Third party |
| Fundación CRIS de Investigación para Vencer el Cáncer | Madrid | Spain | Participant |
| Universitat Autonoma De Barcelona | Cerdanyola Del Valles | Spain | Participant |
| Ecrin European Clinical Research Infrastructure Network | Paris | France | Participant |
| Institut Curie | Paris | France | Participant |
| Institut Gustave Roussy | Villejuif | France | Participant |
| Children's Health Ireland | Dublin | Ireland | Participant |
| Echalliance Company Limited by Guarantee | Dublin | Ireland | Participant |
| Shine 2europe Lda | Coimbra | Portugal | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI